Cargando…

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

Mostrar otras versiones (1)

BACKGROUND: This study aimed to determine whether combination S-1 plus cisplatin (CDDP) therapy, the most widely used therapy for Japanese patients with advanced gastric cancer, and the novel oral antiangiogenic agent TSU-68 could contribute to gastric cancer treatment. METHODS: Ninety-three patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798959/ https://www.ncbi.nlm.nih.gov/pubmed/24045669 http://dx.doi.org/10.1038/bjc.2013.555

Ejemplares similares

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer
por: Koizumi, W, et al.
Publicado: (2014)

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer
por: Koizumi, W, et al.
Publicado: (2003)

Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer
por: Yamada, Yasuhide, et al.
Publicado: (2019)

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
por: Uchino, H, et al.
Publicado: (2005)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

Le programme "TSU-Editor"
por: Hoh, R
Publicado: (1990)

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1)
por: Kurokawa, Y, et al.
Publicado: (2014)

Le TSU: Procédure d'utilisation
por: Frammery, B
Publicado: (1988)

Le TSU: Procédure d'utilisation
por: Frammery, B
Publicado: (1988)

Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer
por: Yamaguchi, Kensei, et al.
Publicado: (2022)

Mode d'emploi du programme TSU archives control pour la manipulation des archives du TSU.
por: Hoh, R
Publicado: (1988)

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2014)

Pompe turbomoleculaire TSU 330 L/s balzers
por: Versolatto, B
Publicado: (1988)

Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma
por: Chen, Shuwei, et al.
Publicado: (2016)

Successful Concurrent Chemoradiotherapy with Cisplatin plus Vinorelbine for Locally Advanced Thymic Carcinoma
por: Fukushima, Toshirou, et al.
Publicado: (2014)

Draft Genome Sequence of a New Bacillus cereus Strain tsu1
por: Li, Hui, et al.
Publicado: (2014)

Modulation of cisplatin cytotoxicity by sulphasalazine.
por: Awasthi, S., et al.
Publicado: (1994)

Horizontal transfer and proliferation of Tsu4 in Saccharomyces paradoxus
por: Bergman, Casey M.
Publicado: (2018)

Cisplatin and S‐1 for urachal carcinoma: A single‐institution case series
por: Urasaki, Tetsuya, et al.
Publicado: (2019)

Arterial chemoembolization with cisplatin microcapsules.
por: Okamoto, Y., et al.
Publicado: (1986)

Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604)
por: Tahara, Makoto, et al.
Publicado: (2015)

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
por: Kubota, K., et al.
Publicado: (2015)

Cisplatin in breast cancer.
por: Willemse, P., et al.
Publicado: (1993)

Volatile Organic Compound from Trichoderma asperelloides TSU1: Impact on Plant Pathogenic Fungi
por: Ruangwong, On-Uma, et al.
Publicado: (2021)

Coronary vasospasm induced by cisplatin for seminoma
por: Sasaki, Wataru, et al.
Publicado: (2019)

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2010)

Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer
por: Sawayama, Hiroshi, et al.
Publicado: (2019)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells.
por: Kondo, S., et al.
Publicado: (1995)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Reversal of Cisplatin Resistance by the 1,4‐Benzothiazepine Derivative, JTV‐519
por: Nakamura, Takashi, et al.
Publicado: (2001)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions
por: Sasaki, Ayaka, et al.
Publicado: (2019)

The ferroptosis inducer erastin irreversibly inhibits system x(c)− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells
por: Sato, Mami, et al.
Publicado: (2018)

Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data
por: Taniguchi, Yuri, et al.
Publicado: (2022)

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
por: Nishio, K., et al.
Publicado: (1990)

GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin
por: Gong, Xin, et al.
Publicado: (2017)

Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment
por: Kim, H-J, et al.
Publicado: (2014)

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy
por: Han, K S, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_eac59vgsj0g85kfd3f9klmfkn9